Autolus Therapeutics (NASDAQ:AUTL) Sees Strong Trading Volume

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) saw strong trading volume on Thursday . 1,371,456 shares traded hands during mid-day trading, a decline of 10% from the previous session’s volume of 1,516,182 shares.The stock last traded at $4.09 and had previously closed at $4.21.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Truist Financial upped their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Friday, April 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $8.16.

Autolus Therapeutics Trading Down 2.0 %

The business has a 50 day moving average of $5.68 and a 200-day moving average of $5.15. The firm has a market capitalization of $1.06 billion, a P/E ratio of -3.36 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.18). On average, analysts anticipate that Autolus Therapeutics plc will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently made changes to their positions in AUTL. Trust Co. of Toledo NA OH bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $84,000. Harbor Capital Advisors Inc. grew its stake in shares of Autolus Therapeutics by 17.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 286,065 shares of the company’s stock worth $667,000 after acquiring an additional 41,524 shares in the last quarter. Rathbones Group PLC bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $171,000. Lynx1 Capital Management LP bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $3,176,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Autolus Therapeutics during the 3rd quarter worth approximately $679,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.